Abstract:Introduction Progressive supranuclear palsy (PSP) is a four-repeat tauopathy characterized by multiple clinicopathologic subtypes. Advanced neuroimaging techniques have shown an early ability to distinguish PSP subtypes non-invasively for improved diagnosis. This study utilized tau-PET imaging and MRI techniques at 7 Tesla (7T) to determine the neuroimaging profile of a participant with comorbid PSP and amyotrophic lateral sclerosis (ALS). Method [18F]-flortaucipir PET imaging was performed on one participant with PSP-ALS, one participant with typical PSP (Richardson’s syndrome; PSP-RS), and 15 healthy control volunteers. Standardized uptake value ratio (SUVR) in each brain region was compared between PSP participants and controls. Quantitative susceptibility mapping (QSM) and inflow-based vascular-space occupancy (iVASO) MRI at 7T were performed on the two PSP participants and on two age-matched healthy controls to evaluate for differences in regional brain iron content and arteriolar cerebral blood volume (CBVa), respectively. Results In the participant with PSP-ALS, the precentral gyrus demonstrated the highest [18F]-flortaucipir uptake of all brain regions relative to controls (z-score 1.94). In the participant with PSP-RS, [18F]-flortaucipir uptake relative to controls was highest in subcortical regions, including the pallidum, thalamus, hippocampus, and brainstem (z-scores 1.08, 1.41, 1.49, 1.32, respectively). Susceptibility values as a measure of brain iron content were higher in the globus pallidus and substantia nigra than in the midbrain and pons in each participant, regardless of group. CBVa values tended to be higher in the subcortical gray matter in PSP participants than in controls, although large measurement variability was noted in controls across multiple regions. Conclusion In vivo tau PET imaging of an individual with PSP-ALS overlap demonstrated increased tau burden in the motor cortex that was not observed in PSP-RS or control participants. Consistent with prior PET studies, tau burden in PSP-RS was mainly observed in subcortical regions, including the brainstem and basal ganglia. QSM data suggest that off-target binding to iron may account for some but not all of the increased [18F]-flortaucipir uptake in the basal ganglia in PSP-RS. These findings support existing evidence that tau PET imaging can distinguish among PSP subtypes by detecting distinct regional patterns of tau deposition in the brain. Larger studies are needed to determine whether CBVa is sensitive to changes in brain microvasculature in PSP.

18F-FDG PET Imaging for Characteristics of Cerebral Glucose Metabolism in Patients with Progressive Supranuclear Palsy

Characteristics of Cerebral Glucose Metabolism in Patients with Progressive Supranuclear Palsy

Characteristics of Cerebral Glucose Metabolism on 18F-FDG PET Imaging in Patients with Parkinson's Disease

Reproducible Network and Regional Topographies of Abnormal Glucose Metabolism Associated with Progressive Supranuclear Palsy: Multivariate and Univariate Analyses in American and Chinese Patient Cohorts.

Validation of Abnormal Glucose Metabolism Associated with Parkinson's Disease in Chinese Participants Based on 18F-Fluorodeoxyglucose Positron Emission Tomography Imaging

Dopamine Transporter PET Imaging in Patients with Progressive Supranuclear Palsy and Parkinson's Disease

Glucose Metabolic Profile by Visual Assessment Combined with Statistical Parametric Mapping Analysis in Pediatric Patients with Epilepsy.

Identification of metabolic progression and subtypes in progressive supranuclear palsy by PET molecular imaging

The Study on Metabolic Brain Networks of Glucose in Patients with early Parkinson's Disease by 18F-FDG PET Imaging

Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy

Characteristics of Brain Glucose Metabolism on 18F-FDG PET Imaging in Patients with Early Parkinson's Disease Accompanied by Visuospatial Working Memory Impairment

Evaluation of Metabolic Changes in Parkinson's Disease Patients with Different Severities of Cognitive Impairments by 18F-FDG PET/CT Brain Imaging

A~(18)F-fluorodeoxyglucose (FDG)/PET Study of Advanced Parkinson's Disease

Added value of FDG-PET for detection of progressive supranuclear palsy

Clinical and MRI analysis of progressive supranuclear palsy：a report of 12 cases

[The Clinical Application Value of Brain 18F-FDG PET/CT in the Diagnostics of Parkinsonian Syndromes].

[A study of microPET for assessing regional cerebral glucose metabolism and the expression of dopamine receptor type 2 in a rat model of Parkinson's disease].

Clinical Utility of 18F‐APN‐1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy

Cerebral tau deposition in co-morbid progressive supranuclear palsy and amyotrophic lateral sclerosis: an [18F]-flortaucipir and 7T MRI study

Metabolic Brain Networks in Patients with Parkinson's Disease Based on 18F-FDG PET Imaging